Hematopoiesis News Volume 7.00 | Jan 5 2016

Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression within the Pre-Metastatic Niche
Investigators showed that a distant primary tumor drives the expansion of hematopoietic stem and progenitor cells within the bone marrow and their mobilization to the bloodstream. [Cancer Res] Abstract

Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis
The authors found that the non-canonical PRC1.1 complex, as identified by mass-spectrometry-based proteomics, is critically important for human leukemic stem cells. [Cell Rep] Full Article | Graphical Abstract

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
The authors showed that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. [Cell Rep] Full Article | Graphical Abstract

Twist-1 Enhances Bone Marrow Mesenchymal Stromal Cell Support of Hematopoiesis by Modulating CXCL12 Expression
Twist-1 over-expressing bone marrow-derived mesenchymal stem/stromal cells exhibited an enhanced capacity to maintain human CD34⁺ hematopoietic stem cells in long-term culture-initiating cell assays. [Stem Cells] Abstract

Fetal Hematopoietic Stem Cell Transplantation Fails to Fully Regenerate the B-Lymphocyte Compartment
Scientists showed that, similar to adult hematopoietic stem cells (HSCs), fetal HSCs selectively fail to regenerate B-1a. [Stem Cell Reports] Full Article

Role of Polycomb RYBP in Maintaining the B-1 to B-2 B-Cell Lineage Switch in Adult Hematopoiesis
Researchers showed that a sustained regulation of B-1 to B-2 switch is needed throughout adult life and that RYBP plays an important role in keeping B-2 dominance, most likely independently of its Polycomb affiliation. [Mol Cell Biol] Abstract

CLINICAL RESEARCH

Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease
Among adult patients with refractory Crohn disease not amenable to surgery who had impaired quality of life, hematopoietic stem cell transplantation, compared with conventional therapy, did not result in a statistically significant improvement in sustained disease remission at one year and was associated with significant toxicity. [JAMA] Abstract | Press Release

Dnmt3a Regulates Myeloproliferation and Liver-Specific Expansion of Hematopoietic Stem and Progenitor Cells
Scientists investigated the impact of conditional hematopoietic Dnmt3a loss on disease phenotype in primary mice. Mx1-Cre-mediated Dnmt3a ablation led to the development of a lethal, fully penetrant myeloproliferative neoplasm with myelodysplasia characterized by peripheral cytopenias and by marked, progressive hepatomegaly. [Leukemia] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase I/II Study in AML and MDS
Rich Pharmaceuticals, Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to commence its Phase I/II clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [Rich Pharmaceuticals, Inc. (PR Newswire Association LLC.)] Press Release

Strategia Therapeutics Announces Progress in a Phase I Clinical Trial of the Anti-Cancer Agent “FF-10501-01” for FUJIFILM in Patients with Advanced Hematologic Malignancies
Strategia Therapeutics, Inc. announced progress in a Phase I clinical trial of FUJIFILM’s anti-cancer agent, FF-10501-01 in the United States in patients with relapsed or refractory myelodysplastic syndromes and acute myeloid leukemia. [Strategia Therapeutics, Inc.] Press Release

Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies
Cellectis announced the submission of a clinical trial application to the Medicines & Healthcare products Regulatory Agency requesting approval to initiate UCART19 First-in-Human clinical investigation in leukemia in the United Kingdom. [Cellectis] Press Release

From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Postdoctoral Scholarship – Cancer Biology (Lund University)

NEW Science Content Writer (Howard Hughes Medical Institute)

NEW Postdoctoral Fellowship – Tumor Immunology and Cancer Metabolism (Yale University)

NEW Research Specialist – Stem Cells from the Hematopoietic System (Howard Hughes Medical Institute)

NEW Postdoctoral Fellow – Leukemia Biology (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Position – Epigenetics and RNA Splicing (National Cancer Institute)

NEW Postdoctoral position – Regenerative Medicine (University of Copenhagen)

Early Stage Researcher – Immunotherapy (ISPIC Consortium Members)

Postdoctoral Fellow – Leukemia and Lymphoma (Emory University)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.